Joe Tippens: The Cancer Story, the Fenbendazole Protocol, and What the Science Says

In 2016, an Oklahoma businessman named Joe Tippens was given roughly three months to live. His small-cell lung cancer had spread throughout his body — to his neck, stomach, liver, bladder, pancreas, tailbone, and right lung. Conventional medicine had reached its limits.

Today, more than nine years later, Joe Tippens is alive and in remission.

His story has been read by people in over 60 countries. It has sparked thousands of conversations between patients and oncologists, prompted new laboratory research, and made a decades-old veterinary deworming drug one of the most searched substances in the world among cancer patients.

Whether you’re a patient researching options, a family member looking for answers, or simply someone trying to understand what the Joe Tippens story actually involves, this article lays out the full picture — what happened, what he took, what science currently says, and what to be cautious about.

Who Is Joe Tippens?

Quick Answer

Joe Tippens is an American businessman from Oklahoma who was diagnosed in 2016 with stage IV small cell lung cancer that had metastasized throughout his body. Given a terminal prognosis of approximately three months, he began taking fenbendazole — a veterinary antiparasitic drug — alongside supplements and his prescribed immunotherapy. Within months, his PET scans showed no evidence of cancer. As of early 2026, he remains alive and in complete remission, ten years after his original diagnosis.

Joe Tippens grew up in a small Oklahoma town in the late 1950s, the youngest of six children. He describes his upbringing as grounded in agriculture and family. By the time of his diagnosis, he was a working professional with no prior significant health history.

The diagnosis came in 2016. Small cell lung cancer is one of the most aggressive forms of the disease, known for rapid progression and poor survival rates. By the time it was identified, Tippens’ cancer had already spread far beyond the lungs. His doctors at MD Anderson Cancer Center told him he had roughly a 1% chance of survival and gave him a prognosis of about three months.

He enrolled in a clinical trial for a new immunotherapy drug called Keytruda (pembrolizumab), but given his prognosis, he believed it was unlikely to make a significant difference in time.

How Did Joe Tippens Discover Fenbendazole?

The story begins with a tip from a veterinarian acquaintance.

Tippens heard about research being conducted at Merck Animal Health, where scientists were studying fenbendazole — a broad-spectrum antiparasitic drug long used in veterinary medicine to deworm dogs, cats, and livestock. In the course of that research, the drug had shown unexpected effects on cancer cells in mice. The story of a scientist at Merck who was diagnosed with brain cancer, tried fenbendazole, and later showed a clean scan circulated among some medical circles.

Tippens decided he had nothing to lose. In January 2017, he began taking fenbendazole alongside a small set of supplements he added himself. He continued receiving Keytruda as part of the clinical trial throughout this period.

Three months later, his PET scan came back clean.

He shared his story publicly in 2019 through his blog, My Cancer Story Rocks (mycancerstory.rocks). Within weeks, it had been read across more than 60 countries. Searches for fenbendazole spiked dramatically worldwide — particularly in South Korea, where his story went especially viral and prompted national media coverage.

As of January 2026, Joe Tippens was alive and in complete remission — marking ten years since his original terminal diagnosis. In February 2026, he appeared publicly at the Annie Appleseed Cancer Conference in West Palm Beach, Florida.

What Is the Joe Tippens Protocol?

The regimen Tippens used has become widely known as the Joe Tippens Protocol or the Fenbendazole Cancer Protocol. It centers on four components.

The Original Protocol Components

1. Fenbendazole (Panacur C or Safeguard) The core of the protocol. Fenbendazole is an antiparasitic drug sold over the counter in pet stores as a dog dewormer. Tippens took 222 mg (one 1-gram packet of Panacur C) three days on, four days off per week. Over time, he updated his approach to daily use.

2. Curcumin A compound found in turmeric, taken at 600 mg per day in a bioavailability-enhanced form. Curcumin has been studied for various anti-inflammatory and potential anti-tumor properties in laboratory settings.

3. CBD Oil 25 mg per day. Tippens included CBD (cannabidiol) oil as part of his regimen. He has since noted this component of the original protocol.

4. Vitamin E (Tocotrienol form) 800 IU daily, originally included in the protocol. Tippens later removed vitamin E from his updated regimen in a July 2020 blog update, citing concerns about a particular interaction.

Important Context: Keytruda Was Also Being Used

One critical fact that is frequently overlooked in popular coverage of this story: Joe Tippens was simultaneously enrolled in a clinical trial for Keytruda (pembrolizumab), a checkpoint inhibitor immunotherapy drug. Keytruda has since become a standard-of-care treatment for several cancer types, including some forms of lung cancer, and is known to produce dramatic responses in certain patients.

This means it is scientifically impossible to attribute Tippens’ remission solely to fenbendazole. His recovery happened in the context of two simultaneous interventions — the conventional immunotherapy drug and the self-administered fenbendazole protocol. Neither he nor any researcher can say with certainty which factor was responsible, or how much each contributed.

This distinction matters enormously when interpreting the story.

What Is Fenbendazole, and How Might It Work Against Cancer?

Fenbendazole (chemical name: methyl N-(6-phenylsulfanyl-1H-benzimidazol-2-yl) carbamate) belongs to the benzimidazole family of antiparasitic drugs. It works in animals by binding to beta-tubulin, a protein involved in cell division. By disrupting tubulin, it prevents parasites from reproducing.

Researchers have been investigating whether this same mechanism could affect cancer cells, which also rely heavily on tubulin during division.

Proposed Mechanisms in Cancer Research

Laboratory and animal studies have proposed several ways fenbendazole might affect tumor cells:

Microtubule disruption: Similar to its anti-parasitic mechanism, fenbendazole may interfere with the assembly of microtubules in cancer cells, disrupting cell division. A 2018 study published in Scientific Reports confirmed this effect in human cell lines.

Glucose metabolism interference: Cancer cells consume glucose at an extraordinarily high rate — roughly 200 times faster than normal cells. Some preclinical research suggests fenbendazole may impair cancer cells’ ability to take up glucose, starving them metabolically.

Apoptosis induction: Several lab studies have found that fenbendazole can trigger programmed cell death (apoptosis) in cancer cell lines.

Proteasome disruption: Some evidence points to interference with the cellular machinery cancer cells use to manage protein turnover.

Anti-angiogenic effects: Early preclinical reports have noted possible reduction in tumor blood vessel formation, which could limit nutrient supply to tumors.

Cancer stem cell suppression: More recent research, including a 2025 study published in the journal Molecules, found that fenbendazole exhibited antitumor activity against cervical cancer stem cells in laboratory models.

What the Research Does NOT Yet Show

All of the above mechanisms are based on laboratory studies and animal models. No large randomized controlled clinical trial has yet tested fenbendazole as a cancer treatment in humans. This is the critical gap between what the preclinical evidence suggests and what has been clinically proven.

A 2021 case series documented three patients with genitourinary malignancies who showed complete responses with fenbendazole, either alone or combined with standard therapies. A 2025 review of approximately 170 anecdotal case reports noted tumor regression across various cancers. However, these reports carry significant limitations in terms of clinical rigor — they cannot establish cause and effect, control for confounding treatments, or account for survivorship bias.

In September 2024, a protocol combining fenbendazole, ivermectin, and mebendazole was published in the Journal of Orthomolecular Medicine — marking the first peer-reviewed publication of this type of combined antiparasitic approach for oncology. However, this remains early-stage research and does not constitute standard medical guidance.

What Regulatory Bodies and Medical Organizations Say

The FDA, the European Medicines Agency (EMA), and the American Cancer Society have each issued cautions about using fenbendazole as a cancer treatment. Their concerns center on:

• The absence of controlled human clinical trial data confirming efficacy
• Unknown long-term effects of human use at cancer-treatment doses
• The documented risk of patients delaying or abandoning proven conventional therapies in favor of unproven alternatives
• The difficulty of determining cause and effect in individual case reports

These are legitimate concerns. Cancer patients who replace conventional treatment — chemotherapy, immunotherapy, radiation, surgery — with fenbendazole risk losing their window for evidence-based interventions that have proven survival benefits.

At the same time, a growing number of integrative oncologists have begun reviewing the preclinical evidence and discussing fenbendazole as a possible complementary approach — not a replacement — under medical supervision.

Survivorship Bias: Why the Stories You Hear Skew Positive

One of the most important concepts to understand when reading about Joe Tippens or similar cases is survivorship bias.

When something appears to work dramatically for someone, that person shares their story. Thousands of people who try fenbendazole and do not experience benefit are far less likely to post about it online. The result is an information environment that over-represents positive outcomes relative to actual outcomes.

This is not unique to fenbendazole. It applies to virtually every anecdotal health intervention that spreads on social media. The stories that go viral are the exceptional ones — by definition.

That doesn’t mean Joe Tippens’ remission wasn’t real. It clearly was, and it’s documented through medical scans. But it does mean that one person’s outcome — even a remarkable one — is not reliable evidence of what most people can expect.

Common Misconceptions About Joe Tippens and His Protocol

“Joe Tippens was cured by fenbendazole alone.” He was simultaneously enrolled in a Keytruda immunotherapy trial. It is scientifically impossible to isolate fenbendazole as the sole cause of his remission. Keytruda is a powerful immunotherapy known to produce dramatic responses in some patients.

“Fenbendazole is a proven cancer treatment.” No large clinical trial has demonstrated this in humans. The preclinical evidence is genuinely interesting to researchers, but interest is not proof.

“If it worked for Joe, it will work for me.” Individual cancer cases vary enormously based on cancer type, stage, genetic profile, immune status, and other treatments being used. What happened in one case does not predict outcomes in others.

“Joe Tippens is dead.” This is false and stems from confusion with a different person. There is an obituary online for a “Joe Frank Tippens Jr.” who passed away in 2018 — this is not the same individual. As of January 2026, Joe Tippens is alive, in remission, and publicly active.

“The protocol is cheap and completely safe.” Fenbendazole is inexpensive compared to conventional cancer drugs, which is part of why it attracts interest. However, it has not been systematically studied for long-term human safety at cancer-treatment doses. Some patients have reported liver enzyme elevations. Safety in the context of specific conventional treatments — particularly certain chemotherapy regimens — has not been fully evaluated.

“Doctors are hiding this.” This framing is inaccurate and unhelpful. Oncologists who have reviewed the preclinical data tend to express genuine scientific interest while calling for rigorous trials — not suppression of the information. The issue is lack of clinical proof, not deliberate concealment.

Key Facts About Joe Tippens and Fenbendazole

• Joe Tippens was diagnosed with stage IV small cell lung cancer in 2016 and given approximately three months to live
• He was simultaneously enrolled in a clinical trial for Keytruda (pembrolizumab) when he began fenbendazole
• His PET scans came back clean within months; he shared his story publicly in 2019
• His blog was read by people in more than 60 countries within weeks of publication
• As of January 2026, he is alive and in complete remission — ten years post-diagnosis
• The Joe Tippens Protocol centers on fenbendazole (222 mg), curcumin (600 mg), and CBD oil (25 mg daily)
• Fenbendazole is a veterinary deworming drug approved for animals, not humans for cancer treatment
• Multiple laboratory studies have identified plausible anti-tumor mechanisms in cell and animal models
• No large human clinical trial has confirmed fenbendazole’s efficacy as a cancer treatment
• The FDA, EMA, and American Cancer Society have cautioned against using it as a replacement for proven treatments
• Survivorship bias significantly shapes the anecdotal evidence circulating online
• A 2024 peer-reviewed paper in the Journal of Orthomolecular Medicine marked the first publication of a combined antiparasitic cancer protocol including fenbendazole

What Should Someone With Cancer Know Before Considering This?

If you or someone you love has been diagnosed with cancer and is researching the Joe Tippens Protocol, here is what is most important to understand.

Talk to your oncologist first. Some oncologists are open to discussing fenbendazole as a complementary measure. Others are not. Either way, your treatment team needs to know what you are taking, because drug interactions and timing relative to conventional treatment matter.

Do not stop or delay conventional treatment. The most consistent message from oncologists — including those who find the preclinical data interesting — is that abandoning proven therapies for an unproven approach carries serious risk. Joe Tippens himself continued Keytruda throughout his fenbendazole protocol.

Monitor liver function. Fenbendazole has been associated with liver enzyme elevations in some cases. Regular blood work is important if you choose to use it.

Understand the limits of anecdotal evidence. One person’s experience — even a genuinely extraordinary one — is not a clinical trial. The people who did not have the same outcome are far less visible online.

Stay connected to reliable sources. Joe Tippens maintains his blog at mycancerstory.rocks and an active Facebook community. For scientific updates, peer-reviewed oncology databases and discussions with your medical team are the most reliable sources.

Frequently Asked Questions

Q1: Who is Joe Tippens?

Ans: Joe Tippens is an Oklahoma businessman who was diagnosed with terminal small cell lung cancer in 2016, given three months to live, and achieved complete remission within months of beginning fenbendazole alongside his prescribed immunotherapy. His story, shared on his blog My Cancer Story Rocks, went viral globally in 2019.

Q2: Is Joe Tippens still alive?

Ans: Yes. As of January 2026, Joe Tippens is alive and in complete remission — ten years after his terminal diagnosis. He appeared publicly at the Annie Appleseed Cancer Conference in February 2026.

Q3: What did Joe Tippens take?

Ans: His original protocol included fenbendazole (222 mg, three days on, four days off), curcumin (600 mg daily), CBD oil (25 mg daily), and vitamin E succinate — while simultaneously receiving Keytruda immunotherapy in a clinical trial.

Q4: What is fenbendazole?

Ans: Fenbendazole is a broad-spectrum antiparasitic drug used in veterinary medicine to treat parasites in dogs, cats, and other animals. It belongs to the benzimidazole drug class and is sold under brand names including Panacur C and Safeguard.

Q5: Has fenbendazole been proven to treat cancer in humans?

Ans: No. While preclinical studies show promising mechanisms, no large controlled human clinical trial has confirmed its efficacy as a cancer treatment. Medical authorities including the FDA and American Cancer Society caution against using it as a replacement for conventional therapy.

Q6: Why did Joe Tippens recover? Was it really fenbendazole?

Ans: This is the core scientific question that remains unanswered. Tippens was also taking Keytruda, a powerful immunotherapy known to produce dramatic remissions in certain patients. It is impossible from one case to determine how much each treatment contributed to his recovery.

Q7: Can anyone try the Joe Tippens Protocol?

Ans: Anyone can, but doing so without medical supervision and without maintaining conventional treatment carries risk. The most responsible approach is to discuss it with your oncology team, maintain conventional treatment, and monitor your health carefully if you choose to add fenbendazole.

Q8: Is there any ongoing clinical research on fenbendazole for cancer?

Ans: Yes. Researchers have been calling for formal clinical trials, and there is growing published preclinical literature. A 2024 peer-reviewed paper marked the first publication of a combined antiparasitic protocol for cancer in an established journal. Formal large-scale human trials remain the critical next step.

Key Takeaways

• Joe Tippens is a real person who received a terminal cancer diagnosis in 2016 and remains alive and in remission as of 2026 — a genuinely extraordinary outcome
• He took fenbendazole alongside Keytruda immunotherapy; both were part of his treatment during remission, making it impossible to isolate which caused the outcome
• The Joe Tippens Protocol has become one of the most widely discussed alternative cancer approaches in the world, particularly among patients with late-stage or treatment-resistant disease
• Fenbendazole has shown plausible anti-tumor mechanisms in laboratory and animal studies, but has not been validated in large human clinical trials
• Regulatory bodies including the FDA and American Cancer Society caution against using it as a replacement for proven treatments
• Survivorship bias shapes much of the positive anecdotal evidence online — the stories of those who did not benefit are far less visible
• The most responsible path for any cancer patient is open dialogue with their oncology team before making any changes to their treatment plan

Joe Tippens’ story is remarkable by any measure. A man given three months to live is still here, nearly a decade later, speaking at cancer conferences and updating his blog. That alone is worth taking seriously.

What it doesn’t do, on its own, is prove a treatment. Science requires more than one story — even an extraordinary one. The most honest summary is this: the science is genuinely interesting, the evidence is preliminary, and no one yet knows enough to call fenbendazole a cancer cure. That work still needs to happen — in well-designed clinical trials, with careful monitoring, and transparent reporting of both successes and failures.

Until then, Joe Tippens’ story remains what it has always been: one remarkable case that raised important questions worth answering.